# Gastroesophageal Reflux Disease

Manage GERD by separating unproven reflux from proven reflux with persistent symptoms, selecting ambulatory testing on or off proton pump inhibitors accordingly, and reserving invasive therapy for objectively documented reflux with an appropriate anatomic and physiologic phenotype.

**Clinical question:** How should physicians confirm GERD and manage persistent symptoms or consideration of antireflux intervention?

Updated: 2026-08-21T02:10:59.514195+00:00

## What matters in practice
- Conclusive GERD evidence includes Los Angeles grade C or D esophagitis, long-segment Barrett mucosa, peptic stricture, or distal esophageal acid exposure time greater than 6% off antisecretory therapy. [2]
- For unproven GERD with persistent symptoms, test off PPI; for previously proven GERD with persistent symptoms despite twice-daily PPI, use pH-impedance monitoring on therapy to identify ongoing reflux burden. [1][2]
- Normal endoscopy plus acid exposure time below 4% and fewer than 40 reflux episodes off PPI supports a non-GERD explanation for symptoms. [2]
- Borderline acid exposure time of 4% to 6% requires integration of symptom association, reflux episode burden, endoscopic findings, and motor/anatomic assessment rather than automatic escalation of acid suppression. [1][2]
- Antireflux procedures should follow objective confirmation of reflux; in incomplete PPI responders with abnormal on-therapy pH-impedance, surgery provided greater symptom relief than continued medical therapy in one randomized trial. [1]

## Decide whether GERD is established before labeling symptoms refractory

Persistent symptoms require a phenotypic diagnosis, not automatic PPI escalation.

Begin with EGD with biopsies when symptoms persist after a PPI trial or when alarm features prompt structural and mucosal evaluation. Biopsy during endoscopy is used to exclude alternative mucosal disorders, including eosinophilic and infectious esophagitis. A normal EGD does not exclude GERD, whereas high-grade erosive esophagitis, long-segment Barrett mucosa, or peptic stricture establishes objective evidence of GERD. [2][5]

Classify the patient as having unproven versus proven GERD before ordering ambulatory reflux testing. Unproven GERD includes persistent symptoms with normal or nondiagnostic endoscopy and no prior abnormal reflux study. Proven GERD includes prior conclusive endoscopic complications or abnormal acid exposure; persistent symptoms in this group may reflect residual reflux, reflux hypersensitivity, motility disease, supragastric belching, rumination, or a nonreflux disorder. [1][2]

Treat extraesophageal complaints—chronic cough, asthma, laryngitis, or dental erosion—as possible rather than presumptive reflux syndromes. The lower background prevalence of GERD in extraesophageal presentations reduces the diagnostic yield of reflux testing compared with typical symptoms, making objective confirmation particularly important before prolonged escalation of reflux-directed treatment or invasive therapy. [8][24]
- Use EGD with biopsies first when persistent symptoms require exclusion of eosinophilic or infectious esophagitis. [5]
- Do not use a normal EGD alone to rule out GERD. [2]
- Do not infer reflux causality from extraesophageal symptoms alone. [8][24]

*Clinical branches that determine the next diagnostic action. [1][2][5]*

| Clinical branch | Key discriminator | Next action |
| --- | --- | --- |
| Conclusive GERD | LA grade C or D esophagitis, long-segment Barrett mucosa, peptic stricture, or off-PPI AET >6% [2] | Manage as proven GERD; use on-therapy pH-impedance if symptoms persist despite twice-daily PPI and escalation is being considered. [1][2] |
| Unproven GERD | Normal or nondiagnostic endoscopy without prior objective reflux evidence [2][5] | Perform ambulatory reflux monitoring off PPI to establish or refute pathologic reflux. [2][5] |
| Persistent extraesophageal symptoms | Cough, asthma, laryngitis, or dental erosions without established reflux causality [8][24] | Prioritize objective reflux evaluation and evaluate competing organ-specific diagnoses. [8][24] |

## Choose off-PPI versus on-PPI reflux monitoring by the question being asked

Testing conditions determine whether the study diagnoses GERD or evaluates treatment failure.

Use ambulatory reflux monitoring off PPI when the question is whether GERD exists. Withhold antisecretory therapy for at least 7 days before off-therapy monitoring. Catheter pH, wireless pH, and pH-impedance can provide acid-exposure data; the selection depends on availability and cost. Wireless pH monitoring may record for up to 96 hours and is generally better tolerated than a transnasal catheter. [2][5]

Use pH-impedance monitoring on therapy when GERD is already proven and the question is whether reflux persists despite antisecretory treatment. Impedance detects reflux episodes regardless of acidity, while pH characterizes acidity; therefore, pH-impedance is the preferred modality when monitoring is indicated during PPI therapy. [2]

Interpret distal esophageal acid exposure time (AET) as a continuum. Off therapy, AET greater than 6% is diagnostic of GERD. AET below 4%, particularly with fewer than 40 reflux episodes and normal endoscopy, supports a non-GERD explanation. AET from 4% to 6% is inconclusive and should be adjudicated with symptom-reflux association and adjunctive endoscopic, motor, and anatomic evidence rather than treated as unequivocal pathologic reflux. [1][2]
- During reflux monitoring, maintain usual meals and activity and record meals, symptoms, and recumbency periods in the diary. [5]
- A positive reflux-symptom association supports reflux-triggered symptoms and may predict a better treatment response. [2]
- Use manometry to define LES location for catheter positioning and to evaluate motor findings when the endoscopic and reflux-monitoring data are inconclusive. [2][5]

### Interpret discordant or borderline studies

Do not equate borderline AET with GERD requiring procedural treatment. In the 4% to 6% range, reflux hypersensitivity, motility disorders, supragastric belching, and rumination may account for symptoms. Even healthy volunteers can show borderline AET across multiday recording, and patients with normal endoscopy or LA grade A esophagitis may overlap with this range. [1]
- If AET is 4% to 6%, review reflux-symptom association, reflux episode count, endoscopic findings, hiatus hernia, and LES/motor assessment before committing to long-term escalation. [1][2]
- If off-PPI AET is below 4% with fewer than 40 reflux episodes and normal endoscopy, redirect evaluation toward non-GERD causes rather than intensifying reflux therapy. [2]

*Ambulatory reflux monitoring selection and interpretation. [1][2][5]*

| Clinical question | Test condition and modality | Actionable interpretation |
| --- | --- | --- |
| Does GERD exist in a patient without prior objective evidence? | Monitor off PPI after withholding antisecretory therapy for at least 7 days; use catheter pH, wireless pH, or pH-impedance according to availability and cost. [2][5] | AET >6% supports GERD; AET <4% plus <40 reflux episodes and normal endoscopy supports a non-GERD explanation. [2] |
| Does reflux persist despite therapy in proven GERD? | Perform pH-impedance monitoring on PPI. [2] | Persistent abnormal reflux burden can identify patients in whom escalation beyond pharmacotherapy may be reasonable. [1][2] |
| Is the study inconclusive? | Off-PPI AET 4% to 6%. [1] | Integrate symptom association, reflux episodes, endoscopic findings, and motor/anatomic data; consider behavioral and motility disorders. [1][2] |

## Use the lowest PPI dose that controls symptoms or maintains healing

Medication intensity should reflect documented disease and symptom response.

For proven GERD, continue long-term PPI therapy at the lowest dose that provides symptom control and/or healing of reflux-related mucosal injury. When symptoms persist, do not assume pharmacologic failure until objective testing distinguishes ongoing reflux from reflux hypersensitivity, behavioral disorders, or another diagnosis. [15][1][2]

For patients taking chronic high-intensity PPI therapy without an ongoing indication, use a planned, supervised dose reduction or discontinuation strategy rather than indefinite continuation by default. In GERD patients receiving multiple daily doses, reported success with step-down to once-daily therapy ranged from 42% to 79%; however, recurrent symptoms after discontinuation are expected in chronic GERD because the defective antireflux barrier remains. [3]

Avoid interpreting a PPI trial as a definitive diagnostic test. In predicting erosive esophagitis or an abnormal pH study, the empiric PPI trial has reported sensitivity of approximately 80% but specificity of only 50% to 60%; persistent or atypical symptoms therefore warrant objective evaluation when the result will alter long-term treatment or procedural decisions. [5]
- Maintain the lowest effective PPI dose for established GERD requiring continued symptom control or healing. [15]
- Consider step-down from multiple-dose PPI therapy when the indication and clinical phenotype permit, with planned reassessment for recurrent symptoms. [3]
- Use objective testing rather than PPI response alone to establish GERD before invasive treatment. [5][2]

*Medication decisions linked to diagnostic phenotype. [1][2][3][15]*

| Situation | Medication decision | Reassessment trigger |
| --- | --- | --- |
| Proven GERD controlled on PPI | Continue the lowest dose that controls symptoms and/or maintains healing. [15] | Reassess if symptom control changes or a dose reduction is clinically appropriate. [15] |
| Multiple-dose PPI without a continuing high-intensity indication | Use a supervised step-down approach; reported transition to once-daily therapy was successful in 42% to 79% of GERD patients. [3] | Recurrence after stopping may reflect persistent antireflux-barrier dysfunction. [3] |
| Persistent symptoms with unproven GERD | Do not escalate solely on symptom persistence or empiric PPI response. [5] | Obtain off-PPI reflux monitoring to determine whether GERD is present. [2][5] |

## Reserve antireflux intervention for objectively documented reflux

Procedural benefit depends on confirming reflux burden and matching the intervention to the clinical phenotype.

Consider antireflux surgery or endoscopic antireflux therapy only after objective reflux documentation, particularly in patients whose symptoms persist despite PPI therapy. In a randomized trial of patients with heartburn incompletely responsive to PPI therapy, abnormal reflux burden on pH-impedance was present in 78 of 366 patients evaluated; among those treated, antireflux surgery produced symptom relief in 67% compared with 28% receiving continued medical management. [1]

For patients with previously proven GERD studied on twice-daily PPI therapy, AET greater than 4.0% and/or more than 80 reflux episodes identified a group in which 85% reported symptom benefit after antireflux surgery in a separate study. These thresholds apply to an on-therapy, previously proven-GERD population and should not be substituted for off-PPI diagnostic thresholds. [1]

Before procedural referral, use the physiologic assessment to exclude phenotypes less likely to benefit from further acid-directed intervention: normal off-PPI reflux burden, borderline AET without corroborating evidence, reflux hypersensitivity, motility disorders, supragastric belching, and rumination. The key tradeoff is avoiding an irreversible or invasive intervention for symptoms not driven by pathologic reflux. [1][2]
- Objective reflux documentation is a prerequisite for escalation beyond medication in persistent symptoms. [1][2]
- In proven GERD with symptoms despite twice-daily PPI, obtain on-therapy pH-impedance rather than an off-therapy study when deciding whether residual reflux supports escalation. [1][2]
- Use endoscopic, reflux-monitoring, motor, and anatomic data together when results are borderline or discordant. [1][2]

*Objective findings that support or argue against invasive reflux therapy. [1][2]*

| Finding | Implication | Next step |
| --- | --- | --- |
| Off-PPI AET >6% or conclusive endoscopic complication | GERD is objectively established. [2] | If symptoms remain burdensome, assess whether reflux persists on treatment and whether antireflux intervention fits the full physiologic and anatomic profile. [1][2] |
| Previously proven GERD on twice-daily PPI with AET >4% and/or >80 reflux episodes | Persistent on-therapy reflux burden may identify patients likely to benefit from antireflux surgery. [1] | Discuss procedural escalation after multidisciplinary physiologic and anatomic assessment. [1][2] |
| Normal endoscopy, off-PPI AET <4%, and <40 reflux episodes | This combination supports a non-GERD explanation. [2] | Avoid reflux-directed procedural escalation; evaluate alternative symptom mechanisms. [1][2] |

## Screen selected chronic GERD patients for Barrett esophagus and verify dysplasia

Endoscopic screening is risk-based, and dysplasia changes the treatment pathway.

Consider Barrett esophagus screening in patients with chronic GERD symptoms plus at least three additional risk factors: male sex, age older than 50 years, White race, current or prior tobacco smoking, central obesity, or a first-degree family history of Barrett esophagus or esophageal adenocarcinoma. [18]

When Barrett-associated dysplasia is diagnosed, obtain confirmation by a second expert gastrointestinal pathologist because the diagnosis materially changes surveillance and treatment decisions. Endoscopic eradication therapy is used for low-grade dysplasia, high-grade dysplasia, and early esophageal adenocarcinoma and is preferred to surveillance and acid suppression alone for these neoplastic stages. [18]

Do not use antireflux procedures as a substitute for Barrett surveillance or dysplasia-directed care. Current Barrett surveillance guidance specifically addresses the role of antireflux procedures in prevention of progression, alongside surveillance methods, sampling strategies, biomarkers, and chemoprevention. [19]
- Screen chronic GERD patients only when the specified cumulative Barrett risk profile is present. [18]
- Confirm Barrett dysplasia with a second expert pathologist before committing to eradication or surveillance pathways. [18]
- Refer low-grade dysplasia, high-grade dysplasia, and early adenocarcinoma for endoscopic eradication therapy evaluation. [18]

*Barrett esophagus decisions that alter management. [18][19]*

| Finding | Required confirmation or risk criterion | Management consequence |
| --- | --- | --- |
| Chronic GERD symptoms | At least three additional risk factors: male sex, age >50 years, White race, tobacco exposure, central obesity, or first-degree family history of Barrett esophagus or esophageal adenocarcinoma. [18] | Consider screening endoscopy for Barrett esophagus. [18] |
| Barrett-associated dysplasia | Second expert pathologist confirmation. [18] | Direct low-grade dysplasia, high-grade dysplasia, and early adenocarcinoma toward endoscopic eradication therapy evaluation. [18] |
| Barrett esophagus under surveillance | Use a surveillance pathway that addresses imaging, sampling, risk stratification, and therapy decisions. [19] | Do not substitute an antireflux procedure for dysplasia-specific surveillance or treatment decisions. [19] |

## References
1. Updates to the modern diagnosis of GERD: Lyon ... — gut.bmj.com — https://gut.bmj.com/content/73/2/361
2. Modern diagnosis of GERD: the Lyon Consensus — gut.bmj.com — https://gut.bmj.com/content/gutjnl/early/2018/02/03/gutjnl-2017-314722.full.pdf
3. Primary carE PPi dEprescRibing (PEPPER) trial: a protocol for determining the optimal strategy for stopping chronic proton pump inhibitor therapy in primary care patients | BMJ Open — bmjopen.bmj.com — https://bmjopen.bmj.com/content/16/4/e101266
4. Minimally invasive endoscopic therapies for gastro- ... — fg.bmj.com — https://fg.bmj.com/content/14/3/249
5. Advances in the physiological assessment and diagnosis of GERD | Nature Reviews Gastroenterology & Hepatology — www.nature.com — https://www.nature.com/articles/nrgastro.2017.130
6. Gastroesophageal reflux monitoring: pH and impedance : GI Motility online — www.nature.com — https://www.nature.com/gimo/contents/pt1/full/gimo31.html
7. Piloting an intraoral pH device to track gastroesophageal ... — www.nature.com — https://www.nature.com/articles/s41598-024-68748-2
8. ACG Practice Guidelines : American Journal of Gastroenterology — journals.lww.com — https://journals.lww.com/ajg/abstract/00000434-200703000-00031~acg-practice-guidelines-esophageal-reflux-testing
9. Gastroesophageal reflux disease: comprehensive... : International Journal of Surgery — journals.lww.com — https://journals.lww.com/international-journal-of-surgery/fulltext/2026/03000/gastroesophageal_reflux_disease__comprehensive.180.aspx
10. Letter to the Editor in Response to ACG Guidelines ... — journals.lww.com — https://journals.lww.com/ajg/fulltext/2022/12000/letter_to_the_editor_in_response_to_acg_guidelines.35.aspx
11. Chinese expert consensus on diagnosis and management ... — onlinelibrary.wiley.com — https://onlinelibrary.wiley.com/doi/full/10.1002/agm2.12293
12. Editorial:Diagnostic Testing in Extraesophageal... : American Journal of Gastroenterology — journals.lww.com — https://journals.lww.com/ajg/abstract/10.1038/ajg.2013.80~editorialdiagnostic-testing-in-extraesophageal-gerd-another
13. An insight into gastroesophageal reflux disease and its ... — academic.oup.com — https://academic.oup.com/rpsppr/article/4/2/rqaf001/7964693
14. UCSD Human Research Protections Program — cdn.clinicaltrials.gov — https://cdn.clinicaltrials.gov/large-docs/11/NCT03619811/Prot_SAP_000.pdf
15. Management of Gastroesophageal Reflux Disease — www.gastrojournal.org — https://www.gastrojournal.org/article/S0016-5085(17)35989-9/fulltext
16. Long-term Outcomes of Patients Receiving a Magnetic ... — www.gastrojournal.org — https://www.gastrojournal.org/article/S1542-3565(15)00763-6/fulltext
17. Efficacy of Transoral Fundoplication vs Omeprazole for ... — www.gastrojournal.org — https://www.gastrojournal.org/article/s0016-5085(14)01208-6/fulltext
18. Barrett Esophagus - StatPearls - NCBI Bookshelf — www.ncbi.nlm.nih.gov — https://www.ncbi.nlm.nih.gov/books/NBK430979
19. AGA Clinical Practice Guideline on Surveillance of Barrett's ... — www.gastrojournal.org — https://www.gastrojournal.org/article/S0016-5085(25)06013-5/fulltext
20. Current Management Practices for... : American Journal of Gastroenterology — journals.lww.com — https://journals.lww.com/ajg/fulltext/00000434-201210001-01487~current-management-practices-for-moderate-to-severe
21. Reflux Monitoring: On or Off Therapy? : American Journal of Gastroenterology — journals.lww.com — https://journals.lww.com/ajg/pdf/10.1038/ajg.2010.318~reflux-monitoring-on-or-off-therapy
22. S985 Certified Medical Education Leads to Changes... : American Journal of Gastroenterology — journals.lww.com — https://journals.lww.com/ajg/fulltext/10.14309/01.ajg.0001131400.83917.b2~s985certified-medical-education-leads-to-changes-in-clinical
23. Diagnostic accuracy of gastroesophageal reflux... : Neurogastroenterology & Motility — journals.lww.com — https://journals.lww.com/00043897-202312000-00016
24. The Montreal Definition and Classification of... : American Journal of Gastroenterology — journals.lww.com — https://journals.lww.com/ajg/abstract/00000434-200608000-00033~the-montreal-definition-and-classification-of

## Editorial note

Prepared from cited clinical literature using Astra's research workflow. Verify recommendations against current guidance and patient-specific factors.